Mavacamten + Placebo

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cardiomyopathy, Hypertrophic

Conditions

Cardiomyopathy, Hypertrophic

Trial Timeline

Apr 17, 2024 → Mar 28, 2031

NCT ID

NCT06253221

About Mavacamten + Placebo

Mavacamten + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Cardiomyopathy, Hypertrophic. The current trial status is active. This product is registered under clinical trial identifier NCT06253221. Target conditions include Cardiomyopathy, Hypertrophic.

What happened to similar drugs?

7 of 20 similar drugs in Cardiomyopathy, Hypertrophic were approved

Approved (7) Terminated (1) Active (12)

✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved

✅RanolazineGilead SciencesApproved

✅Ranexa + PlaceboGilead SciencesApproved

✅TafamidisPfizerApproved

✅MavacamtenBristol Myers SquibbApproved

✅AcoramidisBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06253221	Phase 3	Active	Apr 17, 2024	Mar 28, 2031	Cardiomyopathy, Hypertrophic
NCT04349072	Phase 3	Completed	Jul 6, 2020	May 20, 2024	HOCM, Hypertrophic Obstructive Cardiomyopathy

Competing Products

20 competing products in Cardiomyopathy, Hypertrophic

See all competitors

Product	Company	Stage	Hype Score
Tideglusib + Placebo	AMO Pharma	Phase 2	32
Mavacamten	LianBio	Phase 1	19
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin	AstraZeneca	Approved	43
AZD0233 + AZD0233 Placebo	AstraZeneca	Phase 1	21
AZD4063	AstraZeneca	Phase 1	36
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
candesartan	AstraZeneca	Phase 2	31
LCZ696 + Placebo	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Pre-clinical	26
Eleclazine + Placebo	Gilead Sciences	Phase 2/3	30
Ranolazine	Gilead Sciences	Approved	43
Ranexa + Placebo	Gilead Sciences	Approved	43
Ranolazine	Gilead Sciences	Pre-clinical	18
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35